IBDEI2EF ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40698,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,40698,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,40699,0)
 ;;=L40.1^^159^1993^256
 ;;^UTILITY(U,$J,358.3,40699,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40699,1,3,0)
 ;;=3^Pustulosis Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,40699,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,40699,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,40700,0)
 ;;=L40.2^^159^1993^11
 ;;^UTILITY(U,$J,358.3,40700,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40700,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,40700,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,40700,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,40701,0)
 ;;=L40.3^^159^1993^255
 ;;^UTILITY(U,$J,358.3,40701,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40701,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,40701,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,40701,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,40702,0)
 ;;=L40.4^^159^1993^157
 ;;^UTILITY(U,$J,358.3,40702,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40702,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,40702,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,40702,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,40703,0)
 ;;=L40.8^^159^1993^252
 ;;^UTILITY(U,$J,358.3,40703,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40703,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,40703,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,40703,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,40704,0)
 ;;=L40.9^^159^1993^254
 ;;^UTILITY(U,$J,358.3,40704,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40704,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,40704,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,40704,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,40705,0)
 ;;=L50.9^^159^1993^286
 ;;^UTILITY(U,$J,358.3,40705,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40705,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,40705,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,40705,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,40706,0)
 ;;=L53.8^^159^1993^147
 ;;^UTILITY(U,$J,358.3,40706,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40706,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,40706,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,40706,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,40707,0)
 ;;=L53.9^^159^1993^146
 ;;^UTILITY(U,$J,358.3,40707,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40707,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,40707,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,40707,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,40708,0)
 ;;=L54.^^159^1993^145
 ;;^UTILITY(U,$J,358.3,40708,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40708,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,40708,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,40708,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,40709,0)
 ;;=L56.0^^159^1993^139
 ;;^UTILITY(U,$J,358.3,40709,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40709,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,40709,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,40709,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,40710,0)
 ;;=L56.1^^159^1993^138
 ;;^UTILITY(U,$J,358.3,40710,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40710,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,40710,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,40710,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,40711,0)
 ;;=L56.2^^159^1993^236
 ;;^UTILITY(U,$J,358.3,40711,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40711,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,40711,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,40711,2)
 ;;=^5009216
